Wholomics @ ASCO GI Symposium 2024

We are thrilled to announce that our team at Wholomics recently presented groundbreaking research at the ASCO GI Symposium in San Francisco. Our pilot study on early pancreatic cancer detection has shown remarkable results, and we are excited to share our findings with the medical community.

Pancreatic adenocarcinoma (PDAC) is often diagnosed at advanced stages, leading to high mortality rates. Our study addresses the urgent need for effective early detection methods. Using our proprietary early detection test, we analyzed serum samples to identify cancer-specific molecular signatures in peripheral blood. This technology allowed us to develop computational biomarkers that can accurately distinguish between healthy individuals, patients with chronic pancreatitis, and patients with various stages of pancreatic cancer.

Our technology demonstrated impressive accuracy in differentiating between healthy controls and those with pancreatic conditions, highlighting the robustness of our method.

These results underscore the potential of our technology to revolutionize not only pancreatic cancer screening but also other types of cancer screening, enabling early detection and significantly improving patient outcomes. Our presentation at the ASCO GI Symposium marks a significant milestone for Wholomics, and we are eager to continue our research and validation in additional cohorts.

We invite investors and physicians to learn more about our innovative approach to cancer diagnostics. By collaborating with us, you can be part of a transformative journey towards early cancer detection and better patient care.

For more detailed information, please refer to our abstract.

Stay tuned for further updates as we continue to advance our mission to lead a global revolution in cancer care.